Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2019-12-17
Target enrollment:
Participant gender:
Summary
This is a single-arm phase II trial of Pembrolizumab (Keytruda) in patients with advanced,
unresectable hepatocellular carcinoma. The primary objective is to assess its therapeutic
efficacy in patients with unresectable hepatocellular carcinoma (HCC).